hsa-mir-23a: Hsa-mir-23a is a microRNA that was found to be significantly deregulated in the saliva of resectable pancreatic ductal adenocarcinoma (PDAC) patients compared to healthy controls during the discovery phase [PMC4486170]. However, it was not further investigated as it did not exhibit at least a 4-fold change in expression between the two groups [PMC4486170]. In addition to hsa-mir-23a, other miRNAs were also found to be deregulated in PDAC patients [PMC9004059]. Six miRNAs (hsa-miR-15a, hsa-let-7d, hsa-miR-142, hsa-mir-23a, hsa-miR-199, and hsa-miR-191) were found to be elevated in PDAC patients [PMC9004059]. MiRNA-regulated genes have been implicated in various biological processes such as central nervous system development, congenital abnormalities, and heart problems [PMC9004059].

MIR23A: MIR23A is a microRNA that has been implicated in endothelial barrier dysfunction and disruption of paracellular ZO-1 in recipient brain microvascular endothelial cells (BMECs) following a detectable upregulation of MIR23A in recipient endothelial cell-derived exosomes (R-ECExos) [PMC9260018]. In a study, it was found that MIR23A, along with MIR21 and MIR27A, suppresses the expression of three tumor suppressor genes: programmed cell death 4 (PDCD4), BTG anti-proliferation factor 2 (BTG2), and neural precursor cell expressed/developmentally down-regulated 4-like (NEDD4L) [PMC8273913]. These findings suggest that MIR23A plays a role in the regulation of endothelial barrier function and tumor suppression through its interaction with specific target genes.